Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
3.230
0.00 (0.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
Savara Employees
Savara had 37 employees as of December 31, 2023. The number of employees increased by 9 or 32.14% compared to the previous year.
Employees
37
Change (1Y)
9
Growth (1Y)
32.14%
Revenue / Employee
n/a
Profits / Employee
-$2,241,514
Market Cap
676.56M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CureVac | 1,172 |
Bioventus | 970 |
Axogen | 428 |
Evolus | 273 |
IRADIMED CORPORATION | 148 |
Keros Therapeutics | 136 |
Dianthus Therapeutics | 53 |
SVRA News
- 3 days ago - Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 4 days ago - Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 4 weeks ago - Savara Announces New Employment Inducement Grant - Business Wire
- 4 weeks ago - Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 - Business Wire
- 5 weeks ago - Savara Announces Participation in Upcoming Healthcare Conferences - Business Wire
- 5 weeks ago - Savara Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference - Business Wire
- 2 months ago - Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV - Business Wire